X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.6 In other words, the correlation coefficient of the other stoc
11 Products in late stage /3 FDA approvals expected in 1H 2018 IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL
MarketCap $50 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.80
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
IntelGenx has multi-faceted BD approach for its oral films
With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
ACHS WAS ANOTHER BS ZACKS HYPE. if I could fiend the misleading #$%$ I would fill her full of bullets
worse then ivesting in aa darn bank
Per company last conf call on VTS-270: "It’s under discussions and then what that needs to include is under discussion. Obviously, in the Phase 1, 2 trial which will be coming out in publication in a couple of months, there was a physician score but I don’t want to go further down that, because I don’t want to influence potential discussions with the FDA."
SCMP may be a compelling opportunity. google awe_some_stocks - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
i got a limit buy at 9 & 8
Is a price target of $18 warranted for $SCMP? Earnings estimates have come down sharply They dropped from 1.75 to 1.12 in 2018.
buying AXSM at $3.80 is like buying JAZZ at $1 a few years ago now trading at $151 (AXSM) Market Cap $85 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $85 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.80
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
Sucampo Pharmaceuticals, Inc. (SCMP) (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8th at 2:30PM Eastern.
webcast its corporate presentation at the Bank of America Merrill Lynch 2017 Health Care Conference on Thursday, May 18th at 08:00 AM Pacific Time.
PR time is coming per today's call on VTS-270: "It’s under discussions and then what that needs to include is under discussion. Obviously, in the Phase 1, 2 trial which will be coming out in publication in a couple of months, there was a physician score but I don’t want to go further down that, because I don’t want to influence potential discussions with the FDA."
So we issued $300 million of convertible debt in December - opening the door for the hedge funds to short the stock down 40% or more than $300 million today - so that we can buy a drug that will start to generate revenue in 2019. CFO here is not good.